rs118166657 - RPL31P5 - GCATP1
Magnitude 4.5 · 1 study on file
Reported associations
-
GWAS identifies two susceptibility loci for lamotrigine-induced skin rash in patients with epilepsy. - Epilepsy research (2016) · Jang HW, Kim SW, Cho YJ, Heo K, Lee BI, Lee SK, Jang IJ, Lee MG, Kim WJ, Lee JH · PubMed 26220383
Lamotrigine (LTG)-induced maculopapular eruption (MPE) often causes treatment discontinuation and rising burdens on current healthcare systems. We conducted a genome-wide association study to identify novel susceptibility loci associated with LTG-induced MPE in patients with epilepsy. We enrolled patients with LTG-induced MPE (n=34) and utilized the Korea Association Resource project cohort as a control group (n=1214). We explored associations between LTG-induced MPE and single nucleotide polymorphisms (SNPs) through imputation and replicated these associations in samples from 59 LTG-induced MPE cases and 98 LTG tolerant-controls. We found two novel SNPs associated with LTG-induced MPE: rs12668095 near CRAMP1L/TMEM204/IFT140/HN1L (P=4.89×10(-7)) and rs79007183 near TNS3 (P=3.15×10(-10)),
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
lamotrigine rash risk before starting therapy Moderate
Variant associated with 7.2-fold increased risk of lamotrigine-induced maculopapular eruption
If prescribed lamotrigine, inform prescriber of variant and plan for close rash monitoring